Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ANO1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ANO1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ANO1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ANO1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ANO1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
GO:190495110 | Cervix | CC | positive regulation of establishment of protein localization | 73/2311 | 319/18723 | 9.69e-08 | 5.25e-06 | 73 |
GO:003460510 | Cervix | CC | cellular response to heat | 22/2311 | 69/18723 | 1.65e-05 | 3.20e-04 | 22 |
GO:19016538 | Cervix | CC | cellular response to peptide | 72/2311 | 359/18723 | 1.89e-05 | 3.48e-04 | 72 |
GO:000974310 | Cervix | CC | response to carbohydrate | 53/2311 | 253/18723 | 7.02e-05 | 9.85e-04 | 53 |
GO:003428410 | Cervix | CC | response to monosaccharide | 48/2311 | 225/18723 | 9.48e-05 | 1.25e-03 | 48 |
GO:00094089 | Cervix | CC | response to heat | 27/2311 | 110/18723 | 3.12e-04 | 3.32e-03 | 27 |
GO:000974610 | Cervix | CC | response to hexose | 45/2311 | 219/18723 | 3.73e-04 | 3.86e-03 | 45 |
GO:00425939 | Cervix | CC | glucose homeostasis | 50/2311 | 258/18723 | 7.57e-04 | 6.76e-03 | 50 |
GO:00335009 | Cervix | CC | carbohydrate homeostasis | 50/2311 | 259/18723 | 8.28e-04 | 7.22e-03 | 50 |
GO:00092668 | Cervix | CC | response to temperature stimulus | 37/2311 | 178/18723 | 9.45e-04 | 7.95e-03 | 37 |
GO:00016788 | Cervix | CC | cellular glucose homeostasis | 36/2311 | 172/18723 | 9.65e-04 | 8.09e-03 | 36 |
GO:00097499 | Cervix | CC | response to glucose | 42/2311 | 212/18723 | 1.23e-03 | 9.87e-03 | 42 |
GO:00507148 | Cervix | CC | positive regulation of protein secretion | 29/2311 | 137/18723 | 2.40e-03 | 1.70e-02 | 29 |
GO:00713229 | Cervix | CC | cellular response to carbohydrate stimulus | 33/2311 | 163/18723 | 2.71e-03 | 1.85e-02 | 33 |
GO:00713338 | Cervix | CC | cellular response to glucose stimulus | 31/2311 | 151/18723 | 2.86e-03 | 1.91e-02 | 31 |
GO:00713318 | Cervix | CC | cellular response to hexose stimulus | 31/2311 | 153/18723 | 3.53e-03 | 2.27e-02 | 31 |
GO:00713268 | Cervix | CC | cellular response to monosaccharide stimulus | 31/2311 | 154/18723 | 3.90e-03 | 2.46e-02 | 31 |
GO:00611785 | Cervix | CC | regulation of insulin secretion involved in cellular response to glucose stimulus | 16/2311 | 64/18723 | 4.05e-03 | 2.52e-02 | 16 |
GO:00320245 | Cervix | CC | positive regulation of insulin secretion | 18/2311 | 78/18723 | 5.94e-03 | 3.40e-02 | 18 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANO1 | SNV | Missense_Mutation | | c.643N>G | p.Gln215Glu | p.Q215E | Q5XXA6 | protein_coding | tolerated(0.94) | benign(0.007) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
ANO1 | SNV | Missense_Mutation | | c.1812N>C | p.Glu604Asp | p.E604D | Q5XXA6 | protein_coding | tolerated(0.24) | benign(0.261) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
ANO1 | SNV | Missense_Mutation | rs201962504 | c.2632G>A | p.Asp878Asn | p.D878N | Q5XXA6 | protein_coding | deleterious(0.02) | possibly_damaging(0.617) | TCGA-S3-AA12-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
ANO1 | SNV | Missense_Mutation | novel | c.1130N>T | p.Thr377Ile | p.T377I | Q5XXA6 | protein_coding | tolerated(0.18) | possibly_damaging(0.859) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ANO1 | SNV | Missense_Mutation | novel | c.2410N>A | p.Val804Met | p.V804M | Q5XXA6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ANO1 | SNV | Missense_Mutation | rs770219157 | c.2873N>T | p.Pro958Leu | p.P958L | Q5XXA6 | protein_coding | tolerated(0.26) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ANO1 | SNV | Missense_Mutation | rs778151682 | c.880N>A | p.Glu294Lys | p.E294K | Q5XXA6 | protein_coding | tolerated(0.07) | benign(0.063) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ANO1 | SNV | Missense_Mutation | | c.1360N>A | p.Pro454Thr | p.P454T | Q5XXA6 | protein_coding | tolerated(0.11) | possibly_damaging(0.898) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
ANO1 | SNV | Missense_Mutation | rs373835880 | c.2473N>A | p.Gly825Arg | p.G825R | Q5XXA6 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
ANO1 | SNV | Missense_Mutation | rs768459625 | c.2140N>A | p.Glu714Lys | p.E714K | Q5XXA6 | protein_coding | deleterious(0.01) | possibly_damaging(0.745) | TCGA-JX-A5QV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |